Abstract
Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Infectious Disorders - Drug Targets
Title: Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein
Volume: 12 Issue: 1
Author(s): Catherine Tamalet, Erwann P. Loret, Grant R. Campbell, Stephen A. Spector, Philippe Brouqui, Andreas Stein, Francoise Dignat-George, Pascale Paul, Corinne Brunet, Sonia Mediouni, Herve Moreau, Malika Mokhtari, Herve Tissot-Dupont, Catherine Dhiver, Isabelle Ravaux, Gilbert Baillat and Albert Darque
Affiliation:
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Abstract: Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Export Options
About this article
Cite this article as:
Tamalet Catherine, P. Loret Erwann, R. Campbell Grant, A. Spector Stephen, Brouqui Philippe, Stein Andreas, Dignat-George Francoise, Paul Pascale, Brunet Corinne, Mediouni Sonia, Moreau Herve, Mokhtari Malika, Tissot-Dupont Herve, Dhiver Catherine, Ravaux Isabelle, Baillat Gilbert and Darque Albert, Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein, Infectious Disorders - Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152612798994939
DOI https://dx.doi.org/10.2174/187152612798994939 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Current Molecular Medicine Changes in Immune and Endocrine Systems in Scrapie-Infected Animals
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Hyperhomocysteinemia and Cardiovascular Risk: Effect of Vitamin Supplementation in Risk Reduction
Current Clinical Pharmacology Editorial (Thematic Issue: Macrophage Migration Inhibitory Factor (MIF) and Its Receptors – Interactions and Suitability as Biomarkers)
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
Current Stem Cell Research & Therapy Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Correlation between Potassium Channel Expression and Sensitivity to Drug-induced Cell Death in Tumor Cell Lines
Current Pharmaceutical Design Crystallization And Preliminary X-Ray Diffraction Analysis Of Phosphoglucose Isomerase From Pyrococcus Furiosus
Protein & Peptide Letters Induction of Transplantation Tolerance via Regulatory T Cells
Inflammation & Allergy - Drug Targets (Discontinued) Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study
Current Neurovascular Research Glucose Metabolism and Insulin Resistance in Sepsis
Current Pharmaceutical Design Possible Underestimation by Sports Medicine of the Effects of Early Physical Exercise Practice on the Prevention of Diseases in Adulthood
Current Diabetes Reviews A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design S-Phase Kinase-Associated Protein-2 and Nuclear Factor-kappa Beta as Molecular Targets of Oral Burkitt’s Lymphoma Cell Induced by Quinolinone Derivate-Vesnarinone
Current Signal Transduction Therapy Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Editorial (Thematic Issue: Drug Reprofiling: An Alternative Path to Drug Discovery)
Current Topics in Medicinal Chemistry The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science